# Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency

> **NCT02722304** · PHASE3 · TERMINATED · sponsor: **Baxalta now part of Shire** · enrollment: 7 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease
- Alpha1-antitrypsin Deficiency

## Interventions

- **BIOLOGICAL:** ARALAST NP 60 mg/kg
- **BIOLOGICAL:** ARALAST NP 120 mg/kg
- **BIOLOGICAL:** GLASSIA 60 mg/kg
- **BIOLOGICAL:** GLASSIA 120 mg/kg
- **BIOLOGICAL:** Human Albumin 2%

## Key facts

- **NCT ID:** NCT02722304
- **Lead sponsor:** Baxalta now part of Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-11-02
- **Primary completion:** 2018-09-14
- **Final completion:** 2018-09-14
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2021-05-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02722304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02722304, "Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02722304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*